Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
ABSTRACTBispecific antibodies (BsAbs) capable of recognizing two distinct epitopes or antigens offer promising therapeutic options for various diseases by targeting multiple pathways. The favorable pharmacokinetic (PK) properties of monoclonal antibodies (mAbs) are crucial, as they directly influenc...
Saved in:
Main Authors: | Kristina M.J. Aertker (Author), Minu Ravindra Pilvankar (Author), Tobias M. Prass (Author), Michaela Blech (Author), Fabian Higel (Author), Srinath Kasturirangan (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
"Stapling" scFv for multispecific biotherapeutics of superior properties
by: Lauren E. Boucher, et al.
Published: (2023) -
The improvement of anti-HER2 scFv soluble expression in Escherichia coli
by: Farzaneh Farshdari, et al.
Published: (2020) -
Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments
by: Francesco Nannini, et al.
Published: (2021) -
Chaperone-Assisted Soluble Expression of a Humanized Anti-EGFR ScFv Antibody in E. Coli
by: Kamal Veisi, et al.
Published: (2015) -
Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals
by: Manuela Berto Pucca, et al.
Published: (2011)